Karyopharm Therapeutics’ effort to expand selinexor (Xpovio) into endometrial cancer suffered another setback as top-line Phase 3 data missed the progression-free survival primary endpoint. The readout from XPORT-EC-042 left investors focused on the company’s tightening runway, with cash previously reported at $91.2 million as of Q1—enough to fund operations into the latter part of Q3. Karyopharm said it intends to pursue an sNDA in August for priority review and accelerated approval in a different planned combination setting based on overall survival data from the Sentry trial.